All In Biotech

Drug Trial Radar · NCT07832500

A Lot-to-Lot Consistency Clinical Trial of PCV13

A Randomized, Double-Blind Phase Ⅲb Clinical Trial to Evaluate the Lot-to-Lot Consistency, Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Children Aged 2 to 5 Years

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 1,125 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,125

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Sponsor type
Industry
First posted
Sep 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 2 years, up to 5 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase IIIb clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2 to 5 years. The objective of the study is to evaluate the the Lot-to-Lot consistency, immunogenicity and safety of Sinovac PCV13. The trial is a randomized, double-blind phase IIIb clinical trial.

Conditions

  • Pneumococcal Infectious Diseases

Interventions

  • Sinovac PCV13 lot 1Biological

    One dose of Sinovac PCV13 lot 1 (0.5ml) was administered

  • Sinovac PCV13 lot 2Biological

    One dose of Sinovac PCV13 lot 2 (0.5ml) was administered

  • Sinovac PCV13 lot 3Biological

    One dose of Sinovac PCV13 lot 3(0.5ml) was administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pneumococcal serotype-specific IgG antibody geometric mean concentration (GMC) 30 days after vaccinationTime frame: 30 days after vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention (Xinjiang Uygur Autonomous Region Academy of Preventive Medicine, Xinjiang Uygur Autonomous Region Public Health Inspection and Testing Center)

    Ürümqi, Xinjiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.